Potential antivirals and antiviral strategies against SARS coronavirus infections.
Identifieur interne : 002286 ( PubMed/Corpus ); précédent : 002285; suivant : 002287Potential antivirals and antiviral strategies against SARS coronavirus infections.
Auteurs : Erik De ClercqSource :
- Expert review of anti-infective therapy [ 1744-8336 ] ; 2006.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (administration & dosage), Antiviral Agents (chemistry), Antiviral Agents (metabolism), Drug Delivery Systems (methods), Drug Delivery Systems (trends), Humans, SARS Virus (chemistry), SARS Virus (drug effects), SARS Virus (metabolism), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (metabolism), Severe Acute Respiratory Syndrome (virology).
- MESH :
- chemical , administration & dosage : Antiviral Agents.
- chemical , chemistry : Antiviral Agents.
- chemical , metabolism : Antiviral Agents.
- chemistry : SARS Virus.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- metabolism : SARS Virus, Severe Acute Respiratory Syndrome.
- methods : Drug Delivery Systems.
- trends : Drug Delivery Systems.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Humans.
Abstract
There are a number of antivirals as well as antiviral strategies that could be envisaged to prevent or treat severe acute respiratory syndrome (SARS) (or similar) coronavirus (CoV) infections. Targets for the prophylactic or therapeutic interventions include interaction of the spike (S) glycoprotein (S1 domain) with the host cell receptor, fusion of the S2 domain with the host cell membrane, processing of the replicase polyproteins by the virus-encoded proteases (3C-like cysteine protease [3CLpro] and papain-like cysteine protease) and other virus-encoded enzymes such as the NTPase/helicase and RNA-dependent RNA polymerase. Human monoclonal antibody blocking S1 may play an important role in the immunoprophylaxis of SARS. Fusion inhibitors reminiscent of enfuvirtide in the case of HIV may also be developed for SARS-CoV. Various peptidomimetic and nonpeptidic inhibitors of 3CLpro have been described, the best ones inhibiting SARS-CoV replication with a selectivity index greater than 1000. Human interferons, in particular alpha- and beta-interferon, as well as short interfering RNAs could further be pursued for the control of SARS. Various other compounds, often with an ill-defined mode of action but selectivity indexes up to 100, have been reported to exhibit in vitro activity against SARS-CoV: valinomycin, glycopeptide antibiotics, plant lectins, hesperetin, glycyrrhizin, aurintricarboxylic acid, chloroquine, niclosamide, nelfinavir and calpain inhibitors.
DOI: 10.1586/14787210.4.2.291
PubMed: 16597209
Links to Exploration step
pubmed:16597209Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential antivirals and antiviral strategies against SARS coronavirus infections.</title><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation><nlm:affiliation>Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10B-3000 Leuven, Belgium. erik.declercq@rega.kuleuven.be</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16597209</idno><idno type="pmid">16597209</idno><idno type="doi">10.1586/14787210.4.2.291</idno><idno type="wicri:Area/PubMed/Corpus">002286</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002286</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potential antivirals and antiviral strategies against SARS coronavirus infections.</title><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation><nlm:affiliation>Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10B-3000 Leuven, Belgium. erik.declercq@rega.kuleuven.be</nlm:affiliation></affiliation></author></analytic><series><title level="j">Expert review of anti-infective therapy</title><idno type="eISSN">1744-8336</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (metabolism)</term><term>Drug Delivery Systems (methods)</term><term>Drug Delivery Systems (trends)</term><term>Humans</term><term>SARS Virus (chemistry)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (metabolism)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (metabolism)</term><term>Severe Acute Respiratory Syndrome (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Delivery Systems</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There are a number of antivirals as well as antiviral strategies that could be envisaged to prevent or treat severe acute respiratory syndrome (SARS) (or similar) coronavirus (CoV) infections. Targets for the prophylactic or therapeutic interventions include interaction of the spike (S) glycoprotein (S1 domain) with the host cell receptor, fusion of the S2 domain with the host cell membrane, processing of the replicase polyproteins by the virus-encoded proteases (3C-like cysteine protease [3CLpro] and papain-like cysteine protease) and other virus-encoded enzymes such as the NTPase/helicase and RNA-dependent RNA polymerase. Human monoclonal antibody blocking S1 may play an important role in the immunoprophylaxis of SARS. Fusion inhibitors reminiscent of enfuvirtide in the case of HIV may also be developed for SARS-CoV. Various peptidomimetic and nonpeptidic inhibitors of 3CLpro have been described, the best ones inhibiting SARS-CoV replication with a selectivity index greater than 1000. Human interferons, in particular alpha- and beta-interferon, as well as short interfering RNAs could further be pursued for the control of SARS. Various other compounds, often with an ill-defined mode of action but selectivity indexes up to 100, have been reported to exhibit in vitro activity against SARS-CoV: valinomycin, glycopeptide antibiotics, plant lectins, hesperetin, glycyrrhizin, aurintricarboxylic acid, chloroquine, niclosamide, nelfinavir and calpain inhibitors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16597209</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8336</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert review of anti-infective therapy</Title><ISOAbbreviation>Expert Rev Anti Infect Ther</ISOAbbreviation></Journal><ArticleTitle>Potential antivirals and antiviral strategies against SARS coronavirus infections.</ArticleTitle><Pagination><MedlinePgn>291-302</MedlinePgn></Pagination><Abstract><AbstractText>There are a number of antivirals as well as antiviral strategies that could be envisaged to prevent or treat severe acute respiratory syndrome (SARS) (or similar) coronavirus (CoV) infections. Targets for the prophylactic or therapeutic interventions include interaction of the spike (S) glycoprotein (S1 domain) with the host cell receptor, fusion of the S2 domain with the host cell membrane, processing of the replicase polyproteins by the virus-encoded proteases (3C-like cysteine protease [3CLpro] and papain-like cysteine protease) and other virus-encoded enzymes such as the NTPase/helicase and RNA-dependent RNA polymerase. Human monoclonal antibody blocking S1 may play an important role in the immunoprophylaxis of SARS. Fusion inhibitors reminiscent of enfuvirtide in the case of HIV may also be developed for SARS-CoV. Various peptidomimetic and nonpeptidic inhibitors of 3CLpro have been described, the best ones inhibiting SARS-CoV replication with a selectivity index greater than 1000. Human interferons, in particular alpha- and beta-interferon, as well as short interfering RNAs could further be pursued for the control of SARS. Various other compounds, often with an ill-defined mode of action but selectivity indexes up to 100, have been reported to exhibit in vitro activity against SARS-CoV: valinomycin, glycopeptide antibiotics, plant lectins, hesperetin, glycyrrhizin, aurintricarboxylic acid, chloroquine, niclosamide, nelfinavir and calpain inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Clercq</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10B-3000 Leuven, Belgium. erik.declercq@rega.kuleuven.be</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Anti Infect Ther</MedlineTA><NlmUniqueID>101181284</NlmUniqueID><ISSNLinking>1478-7210</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="Y">SARS Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>94</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16597209</ArticleId><ArticleId IdType="doi">10.1586/14787210.4.2.291</ArticleId><ArticleId IdType="pmc">PMC7105749</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chem Biol. 2005 Mar;12(3):303-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15797214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 1991 Jan;34(1):337-42</Citation><ArticleIdList><ArticleId IdType="pubmed">1704066</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 2005 Nov 3;48(22):6832-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16250642</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochim Biophys Acta. 2006 Jan;1760(1):55-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16290276</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2003 Dec;1(3):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15035025</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Lett. 2004 Feb 27;560(1-3):141-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14988013</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 1988 Dec 11;10(6):289-98</Citation><ArticleIdList><ArticleId IdType="pubmed">3250333</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 16;279(3):1637-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14561748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Aug 6;320(4):1199-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15249217</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2005 Dec 9;280(49):41005-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16183648</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2006 Jan;78(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16299724</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2005 Jun 15;15(12):3058-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15896959</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2005 Jun;66(2-3):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15911031</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):293-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12892961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Jul 22;333(1):194-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15950190</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Nov 10;329(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15476870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2005 Nov 11;353(5):1106-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16216269</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):317-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15030704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Dec;79(23):14614-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16282461</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 May 10;335(2):165-76</Citation><ArticleIdList><ArticleId IdType="pubmed">15840516</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Nov 26;290(20):2665-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14645307</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Chem Chemother. 2005;16(1):13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15739618</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2005 Sep;11(9):944-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16116432</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Apr 29;330(1):39-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15781229</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 2005 Jun 30;48(13):4469-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15974598</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1972 Aug 25;177(4050):705-6</Citation><ArticleIdList><ArticleId IdType="pubmed">4340949</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 1986 Apr 14;136(1):64-71</Citation><ArticleIdList><ArticleId IdType="pubmed">3010977</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hong Kong Med J. 2003 Jun;9(3):199-201</Citation><ArticleIdList><ArticleId IdType="pubmed">12777656</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Evid Based Complement Alternat Med. 2005 Jun;2(2):209-215</Citation><ArticleIdList><ArticleId IdType="pubmed">15937562</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Peptides. 2006 Apr;27(4):622-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16242214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 1987 Mar;7(3):127-37</Citation><ArticleIdList><ArticleId IdType="pubmed">3475037</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2005 Dec 15;15(24):5365-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16216498</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Virol. 2004 Jul;30(3):211-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15135736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Aug;79(15):9665-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16014928</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15215127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2004 Sep;2(9):704-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15372081</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Comput Biol Chem. 2005 Jun;29(3):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15979041</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2003 Oct 10;278(41):39578-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12917423</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 18;319(1):283-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15158473</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 2005 Nov 3;48(22):6767-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16250632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Dec;79(24):15189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16306590</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 2003 Dec 15;31(24):7117-30</Citation><ArticleIdList><ArticleId IdType="pubmed">14654687</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem. 2005 Sep 1;13(17):5240-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15994085</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2004 Jul;8(4):223-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15234326</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 9;319(4):1216-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15194496</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1989 May;86(9):3322-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2566170</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Apr 23;279(17):17996-8007</Citation><ArticleIdList><ArticleId IdType="pubmed">14754895</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Immunol. 2006 Feb-Mar;118(2-3):180-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16298165</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 2004 Dec 2;47(25):6113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15566280</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 1991 Jan;34(1):329-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1704065</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 2005 Feb 24;48(4):1256-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15715493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Mar;10(3):290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14981511</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2003 Aug 15;308(1):148-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12890493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Interferon Cytokine Res. 2004 Jul;24(7):388-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15296649</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4197928</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2004 Oct 21;351(17):1772-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15496626</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Chem Chemother. 2004 Jan;15(1):15-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15074711</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15144898</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Chem Chemother. 2005;16(1):23-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15739619</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Jun;79(11):7095-103</Citation><ArticleIdList><ArticleId IdType="pubmed">15890949</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2005 Oct;68(1):36-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16115693</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Dec;79(24):15199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">16306591</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2005 Nov 11;353(5):1137-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16219322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002286 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002286 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16597209
|texte= Potential antivirals and antiviral strategies against SARS coronavirus infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16597209" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |